These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 34447289)

  • 1. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.
    Yuan M; Men Y; Kang J; Sun X; Zhao M; Bao Y; Yang X; Sun S; Ma Z; Wang J; Deng L; Wang W; Zhai Y; Liu W; Zhang T; Wang X; Bi N; Lv J; Liang J; Feng Q; Chen D; Xiao Z; Zhou Z; Wang L; Hui Z
    Thorac Cancer; 2021 Jan; 12(2):227-234. PubMed ID: 33247556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    Wang W; Men Y; Wang J; Zhou Z; Chen D; Xiao Z; Feng Q; Lv J; Liang J; Bi N; Gao S; Wang L; Hui Z
    BMC Cancer; 2019 May; 19(1):478. PubMed ID: 31113432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
    Yang H; Wang K; Li B; Li S; Li Y; Yuan L
    Front Oncol; 2021; 11():707041. PubMed ID: 34917497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer.
    Zhu M; Li S; Yuan L; Liu S; Li J; Zhang D; Chen J; Jiang J; Xu Z
    World J Surg Oncol; 2023 Aug; 21(1):238. PubMed ID: 37537652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis.
    Li J; Li L; Wang J; Liu N; Liu H; Xu F; Li M; Yuan S
    Respir Res; 2024 Jun; 25(1):244. PubMed ID: 38886760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer.
    Yuan C; Tao X; Zheng D; Pan Y; Ye T; Hu H; Xiang J; Zhang Y; Chen H; Sun Y
    J Surg Oncol; 2019 Mar; 119(3):379-387. PubMed ID: 30536966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
    Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
    J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    Duan H; Liang L; Xie S; Wang C
    BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
    Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
    Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.